Targeted Oncogene Therapy Before Surgery in Pediatric Patients With Advanced Invasive Thyroid Cancer at Initial Presentation

Ken Kazahaya; Kara K. Prickett; Vera A. Paulson; John P. Dahl; Scott C. Manning; Erin R. Rudzinski; Jeffrey C. Rastatter; Sanjay R. Parikh; Douglas S. Hawkins; Marcia S. Brose; Andrew J. Bauer

doi:10.1001/jamaoto.2020.1340

journal article Aug 01, 2020

Targeted Oncogene Therapy Before Surgery in Pediatric Patients With Advanced Invasive Thyroid Cancer at Initial Presentation

Ken Kazahaya Kara K. Prickett Vera A. Paulson

John P. Dahl

Scott C. Manning Erin R. Rudzinski Jeffrey C. Rastatter Sanjay R. Parikh Douglas S. Hawkins Marcia S. Brose Andrew J. Bauer

JAMA Otolaryngology–Head & Neck Surgery Vol. 146 No. 8 pp. 748 · American Medical Association (AMA)

View at Publisher Save 10.1001/jamaoto.2020.1340

Topics

No keywords indexed for this article. Browse by subject →

References

22

[1]

Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer

Gary L. Francis, Steven G. Waguespack, Andrew J. Bauer et al.

Thyroid 2015 10.1089/thy.2014.0460

[2]

Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

Samuel A. Wells, Sylvia L. Asa, Henning Dralle et al.

Thyroid 2015 10.1089/thy.2014.0335

[3]

Rao "Navigating systemic therapy in advanced thyroid carcinoma: from standard of care to personalized therapy and beyond." J Endocr Soc (2018) 10.1210/js.2018-00180

[4]

Naoum "Novel targeted therapies and immunotherapy for advanced thyroid cancers." Mol Cancer (2018) 10.1186/s12943-018-0786-0

[5]

Mahajan "Response to lenvatinib in children with papillary thyroid carcinoma." Thyroid (2018) 10.1089/thy.2018.0064

[6]

Waguespack "The successful use of sorafenib to treat pediatric papillary thyroid carcinoma." Thyroid (2009) 10.1089/thy.2008.0429

[7]

Robinson "Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer." J Clin Endocrinol Metab (2016) 10.1210/jc.2015-3989

[8]

Drilon "Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children." N Engl J Med (2018) 10.1056/nejmoa1714448

[9]

Thyroid Cancer in the Pediatric Population

Vera A. Paulson, Erin R. Rudzinski, Douglas S. Hawkins

Genes 2019 10.3390/genes10090723

[10]

Hillier "A novel ALK fusion in pediatric medullary thyroid carcinoma." Thyroid (2019) 10.1089/thy.2019.0041

[11]

Taylor (2019)

[12]

Wirth (2019)

[13]

Phase 1/2 study of the highly-selective RET inhibitor, pralsetinib (BLU-667), in patients with thyroid cancer, non–small cell lung cancer, and other advanced solid tumors (ARROW). ClinicalTrials.gov identifier: NCT03037385. Accessed May 23, 2020. https://clinicaltrials.gov/ct2/show/NCT03037385

[14]

Phase 1/2 study of LOXO-292 in patients with advanced solid tumors, RET fusion–positive solid tumors, and medullary thyroid cancer (LIBRETTO-001). ClinicalTrials.gov identifier: NCT03157128. Accessed May 23, 2020. https://clinicaltrials.gov/ct2/show/NCT03157128

[15]

A study of oral LOXO-292 in pediatric patients with advanced solid or primary central nervous system tumors (LIBRETTO-121). ClinicalTrials.gov identifier: NCT03899792. Accessed May 23, 2020. https://clinicaltrials.gov/ct2/show/NCT03899792

[16]

Phase 2 study assessing efficacy and safety of crizotinib in patients harboring an alteration on ALK, MET or ROS1 (AcSé). ClinicalTrials.gov identifier: NCT02034981. Accessed May 23, 2020. https://clinicaltrials.gov/ct2/show/NCT02034981

[17]

Ceritinib in mutation and oncogene directed therapy in thyroid cancer. ClinicalTrials.gov identifier: NCT02289144. Accessed May 23, 2020. https://clinicaltrials.gov/ct2/show/NCT02289144

[18]

A roll over study of alectinib in patients with anaplastic lymphoma kinase (ALK)–positive or rearranged during transfection (RET)–positive cancer. ClinicalTrials.gov identifier: NCT03194893. Accessed May 23, 2020. https://clinicaltrials.gov/ct2/show/NCT03194893

[19]

Targeted therapy directed by genetic testing in treating pediatric patients with relapsed or refractory advanced solid tumors, non-Hodgkin lymphomas, or histiocytic disorders (The Pediatric MATCH Screening Trial). ClinicalTrials.gov identifier: NCT03155620. Accessed May 23, 2020. https://clinicaltrials.gov/ct2/show/NCT03155620

[20]

Evaluation of efficacy, safety of vandetanib in patients with differentiated thyroid cancer (VERIFY). ClinicalTrials.gov identifier: NCT01876784. Accessed May 23, 2020. https://www.clinicaltrials.gov/ct2/show/NCT01876784

[21]

A study of cabozantinib compared with placebo in subjects with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy. ClinicalTrials.gov identifier: NCT03690388. Accessed May 23, 2020. https://clinicaltrials.gov/ct2/show/NCT03690388

[22]

Larotrectinib in treating patients with previously untreated TRK fusion solid tumors and TRK fusion relapsed acute leukemia. ClinicalTrials.gov identifier: NCT03834961. Accessed May 23, 2020. https://clinicaltrials.gov/ct2/show/NCT03834961

Metrics

22

Citations

22

References

Details

Published: Aug 01, 2020
Vol/Issue: 146(8)
Pages: 748

Authors

K

Ken Kazahaya

Department of Pediatric Otolaryngology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Otorhinolaryngology–Head and Neck Surgery, University of Pennsylvania, Philadelphia

K

Kara K. Prickett

Department of Otolaryngology–Head and Neck Surgery, Emory University School of Medicine, Atlanta, Georgia

V

Vera A. Paulson

Department of Laboratory Medicine, University of Washington (UW) Medical Center, Seattle

J

John P. Dahl

Department of Otolaryngology–Head and Neck Surgery, University of Washington, Seattle

S

Scott C. Manning

Department of Otolaryngology–Head and Neck Surgery, University of Washington, Seattle

E

Erin R. Rudzinski

Department of Laboratories, Seattle Children’s Hospital, Seattle, Washington

J

Jeffrey C. Rastatter

Otorhinolaryngology–Head & Neck Surgery, Lurie Children’s Hospital of Chicago, Chicago, Illinois; Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

S

Sanjay R. Parikh

Department of Otolaryngology–Head and Neck Surgery, University of Washington, Seattle

D

Douglas S. Hawkins

Division of Hematology/Oncology, Fred Hutchinson Cancer Research Center, Seattle Children’s Hospital, University of Washington, Seattle

M

Marcia S. Brose

Department of Otorhinolaryngology–Head and Neck Surgery, University of Pennsylvania, Philadelphia; Abramson Cancer Center, University of Pennsylvania, Philadelphia

A

Andrew J. Bauer

Division of Endocrinology and Diabetes, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania; Department of Pediatrics, University of Pennsylvania, Philadelphia

Cite This Article

Ken Kazahaya, Kara K. Prickett, Vera A. Paulson, et al. (2020). Targeted Oncogene Therapy Before Surgery in Pediatric Patients With Advanced Invasive Thyroid Cancer at Initial Presentation. JAMA Otolaryngology–Head & Neck Surgery, 146(8), 748. https://doi.org/10.1001/jamaoto.2020.1340

Targeted Oncogene Therapy Before Surgery in Pediatric Patients With Advanced Invasive Thyroid Cancer at Initial Presentation

You May Also Like